Phreesia (PHR)
(Delayed Data from NYSE)
$21.03 USD
+0.04 (0.19%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $21.03 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$21.03 USD
+0.04 (0.19%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $21.03 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Zacks News
Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inspire (INSP) delivered earnings and revenue surprises of 24.29% and 6.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 7.69% and 2.56%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
Sonendo, Inc. (SONX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sonendo, Inc. (SONX) delivered earnings and revenue surprises of 45.45% and 5.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cooper Companies (COO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal first-quarter results are likely to reflect segmental strength.
What's in Store for Patterson Companies (PDCO) in Q3 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal third-quarter results are likely to reflect an improvement at the Animal Health segment.
What Makes Phreesia (PHR) a New Buy Stock
by Zacks Equity Research
Phreesia (PHR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Phreesia (PHR) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Phreesia (PHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 13.64% and 2.73%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
MEI Pharma, Inc. (MEIP) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 0% and 10.46%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of -6.38% and 7.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Cue Health Inc. (HLTH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cue Health Inc. (HLTH) delivered earnings and revenue surprises of 21.82% and 19.92%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Can Phreesia (PHR) Climb 26% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.7% in Phreesia (PHR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Phreesia (PHR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 10.10% and 3.04%, respectively, for the quarter ended July 2022. Do the numbers hold clues to what lies ahead for the stock?
Nemaura Medical, Inc. (NMRD) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nemaura Medical, Inc. (NMRD) delivered earnings and revenue surprises of -6.25% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Olink Holding AB publ Sponsored ADR (OLK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Olink Holding AB publ Sponsored ADR (OLK) delivered earnings and revenue surprises of 69.23% and 3.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SOPHiA GENETICS SA (SOPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
SOPHiA GENETICS SA (SOPH) delivered earnings and revenue surprises of 0% and 0.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 38% Upside in Phreesia (PHR): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Phreesia (PHR) points to a 37.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why Phreesia (PHR) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Phreesia (PHR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Wall Street Analysts Think Phreesia (PHR) Could Surge 26%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 25.5% upside potential for Phreesia (PHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Phreesia (PHR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phreesia (PHR) delivered earnings and revenue surprises of 9.17% and 1.49%, respectively, for the quarter ended April 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Phreesia (PHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nextgen Healthcare (NXGN) Q4 Earnings Miss Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of -5% and 0.24%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Surges 7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Phreesia (PHR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Privia Health (PRVA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Privia Health (PRVA) delivered earnings and revenue surprises of 500% and 5.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -40% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?